JP7783183B2 - 自己免疫障害における抗ｂｃｍａ治療 - Google Patents

自己免疫障害における抗ｂｃｍａ治療

Info

Publication number
JP7783183B2
JP7783183B2 JP2022548786A JP2022548786A JP7783183B2 JP 7783183 B2 JP7783183 B2 JP 7783183B2 JP 2022548786 A JP2022548786 A JP 2022548786A JP 2022548786 A JP2022548786 A JP 2022548786A JP 7783183 B2 JP7783183 B2 JP 7783183B2
Authority
JP
Japan
Prior art keywords
antibody
seq
bcma
region
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514224A (ja
JP2023514224A5 (https=
Inventor
メンサー，コフィ
プレンゲ，ロバート
ロイ，ソフィー
ザラー，デニス
ドベイ，ジェニファー
サエンス，スティーブン
エノー，ジル
ドイカン，カミーユ
カルビノ，ジェナ
ジン，シー
パケット，ジョセフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023514224A publication Critical patent/JP2023514224A/ja
Publication of JP2023514224A5 publication Critical patent/JP2023514224A5/ja
Application granted granted Critical
Publication of JP7783183B2 publication Critical patent/JP7783183B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022548786A 2020-02-12 2021-02-11 自己免疫障害における抗ｂｃｍａ治療 Active JP7783183B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062975663P 2020-02-12 2020-02-12
US62/975,663 2020-02-12
PCT/US2021/017665 WO2021163329A1 (en) 2020-02-12 2021-02-11 Anti-bcma therapy in autoimmune disorders

Publications (3)

Publication Number Publication Date
JP2023514224A JP2023514224A (ja) 2023-04-05
JP2023514224A5 JP2023514224A5 (https=) 2025-09-25
JP7783183B2 true JP7783183B2 (ja) 2025-12-09

Family

ID=77291870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548786A Active JP7783183B2 (ja) 2020-02-12 2021-02-11 自己免疫障害における抗ｂｃｍａ治療

Country Status (11)

Country Link
US (1) US20240052064A1 (https=)
EP (1) EP4103224A4 (https=)
JP (1) JP7783183B2 (https=)
KR (1) KR20220141306A (https=)
CN (1) CN115551539A (https=)
AU (1) AU2021221123A1 (https=)
BR (1) BR112022014646A2 (https=)
CA (1) CA3169696A1 (https=)
IL (1) IL295471A (https=)
MX (1) MX2022009784A (https=)
WO (1) WO2021163329A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
WO2023044633A1 (zh) * 2021-09-22 2023-03-30 南京驯鹿医疗技术有限公司 Bcma car-t在制备用于治疗自身免疫病的药物中的应用
WO2026033437A1 (en) * 2024-08-07 2026-02-12 Janssen Biotech, Inc. Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
WO2026037514A1 (en) * 2024-08-13 2026-02-19 Friedrich-Alexander-Universität Erlangen-Nürnberg, in Vertretung des Freistaates Bayern A bispecific binding agent targeting cd3 and bcma for the treatment of autoimmune diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532766A (ja) 2015-08-03 2018-11-08 エンクマフ エスアーエールエル Ｂｃｍａに対するモノクローナル抗体
WO2018237022A1 (en) 2017-06-21 2018-12-27 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202003501XA (en) * 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532766A (ja) 2015-08-03 2018-11-08 エンクマフ エスアーエールエル Ｂｃｍａに対するモノクローナル抗体
WO2018237022A1 (en) 2017-06-21 2018-12-27 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
mAbs，2019年，Vol.11, No.4, pp.639-652

Also Published As

Publication number Publication date
BR112022014646A2 (pt) 2022-09-13
KR20220141306A (ko) 2022-10-19
JP2023514224A (ja) 2023-04-05
US20240052064A1 (en) 2024-02-15
EP4103224A4 (en) 2023-08-16
CN115551539A (zh) 2022-12-30
MX2022009784A (es) 2022-09-09
IL295471A (en) 2022-10-01
WO2021163329A1 (en) 2021-08-19
CA3169696A1 (en) 2021-08-19
AU2021221123A1 (en) 2022-10-06
EP4103224A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
JP7106594B2 (ja) Ｐｄ－ｌ１に対するヒト抗体
JP7783183B2 (ja) 自己免疫障害における抗ｂｃｍａ治療
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
JP7296363B2 (ja) 抗ｃｔｌａ－４抗体およびその使用
TWI788286B (zh) 三特異性和/或三價結合蛋白
US11104745B2 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
JP2024020377A (ja) 抗ｃｄ３８抗体および使用方法
JP7792333B2 (ja) Ｂｃｍａおよびｃｄ３に対する抗体を用いる処置方法
TW202115114A (zh) 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法
US20140199299A1 (en) Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
CN110041429A (zh) 抗cd-3抗体，与cd3及cd20结合的双特异性抗原结合分子，及其用途
WO2021092060A1 (en) Methods of treatment
IL254335B (en) Isolated peptides derived from the dimerization regions of b7
TW202220691A (zh) 用於使用ＰＤ—１ｘＣＴＬＡ—４雙特異性分子的方法
US20230172923A1 (en) Methods of treating cytokine-related adverse events
EA050324B1 (ru) Терапия антителами против bcma при аутоиммунных расстройствах
EA049790B1 (ru) Способы лечения антителами к bcma и cd3
HK40083315A (en) Methods of treatment with antibodies against bcma and cd3
WO2025042742A1 (en) Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
KR20260057078A (ko) Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법
WO2026033437A1 (en) Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
BR122025021892A2 (pt) Células hospedeiras

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251127

R150 Certificate of patent or registration of utility model

Ref document number: 7783183

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150